Adriamycin combinations in advanced breast cancer:A southwest oncology group study

Autor: John N. Bickers, Robert L. Palmer, John H. Costanzi, B. Hoogstraten, Henry E. Wilson, N. Gad El Mawli, Clarence B. Vaughn, L. Heilburn, Tranum Bl, T. R. Maloney, Tate Thigpen, B. McDonald, S. Rasmusen
Rok vydání: 1982
Předmět:
Zdroj: Cancer. 49:835-839
ISSN: 1097-0142
0008-543X
DOI: 10.1002/1097-0142(19820301)49:5<835::aid-cncr2820490502>3.0.co;2-z
Popis: The Southwest Oncology Group tested three combinations of drugs with Adriamycin to identify a best regimen for treatment of advanced breast cancer. Adriamycin, cyclophosphamide, and 5-fluorouracil (5FU)(FAC); Adriamycin and cyclosphosphamide (AC); and Adriamycin followed by cyclophosphamide, vincristine, methotrexate, 5FU, and prednisone (A + COMFP) were used in a prospective randomized study of 497 patients with previously untreated metastatic breast cancer. The complete response (CR) plus partial response (PR) was (57/140) 44% with AC, (77/160) 48% with FAC, and (78/148) 46% with A + COMFP. The median length of response was 29, 52, and 37 weeks respectively, with AC, FAC and A + COMFP. The median survival of all patients was 79 weeks; 89 weeks AC, 84 weeks FAC, and 76 weeks with A + COMFP. Toxicity was similar in all three regimens except that leukopenia was more common with FAC.
Databáze: OpenAIRE
Externí odkaz: